Phase 2 N=132 A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Respiratory Distress Syndrome, Adult
Primary: Ventilator-free Days During Days 1-28 — 10.8; 10.7 Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=593 A Dose-ranging Study of Fluticasone Furoate (FF)
Asthma
Primary: Change From Baseline in Daily Pre-dose Morning (AM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 12-week Treatment Period — 3.3…
Phase 2 N=10 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Scleroderma, Diffuse · Scleroderma, Systemic
Primary: Change in Modified Rodnan Skin Score — -8.6; -2.3 MRSS score
Phase 2 N=8 Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy
Peripheral Neuropathy · Type 1 Diabetes
Primary: Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm — 6.3; 3.0; 5.2; 3.0 fibers per mm
Phase 2 N=10 A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Exfoliation Syndrome · Ocular Hypertension · Open Angle Glaucoma
Primary: Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) — 24.2; 25.8 mmHg
Phase 2 N=44 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Atypical Hemolytic-Uremic Syndrome
Primary: Percentage of Patients With Complete TMA Response — 73.2 Percentage of Participants
Phase 2 N=6 Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS)
ARDS
Primary: Number of Participants That Did Not Require Endotrachael Intubation — 3 participants
Phase 2 N=14 Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Overall Progression-Free Survival (PFS). — 370 Days
Phase 2 N=525 Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Meningococcal Meningitis · Meningococcal Infections
Primary: Seroresponse (Percent Seroconversion). — 70.7; 70.1; 66.5; 72.5 percentage of per protocol participants
Phase 2 N=109 Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Change From Baseline to Month 3 in Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)…
Phase 2 N=11 Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Breast Cancer
Primary: Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I) — 120 mg/m^2
Phase 2 N=57 Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer
Prostate Cancer
Primary: PSA Response — 56 percentage of participants
Phase 2 N=14 NMDA Receptors in Motor Learning in Humans
Stroke
Primary: Grip Strength of Affected Hand — 3.95; 5.72; 4.90; 8.44 Newton
Phase 2 N=19 Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Acinar Cell Adenocarcinoma of the Pancreas · Duct Cell Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer
Primary: Response Rate of at Least 30% — 0 participants
Phase 2 N=662 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Pandemic H5N1 Influenza
Primary: The Percentages Of Subjects Aged 6 to <36 Months, Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain — 1; 0; 98; 94 Percentages of subjects